Inotuzumab ozogamicin (Besponsa) is a CD22-targeted antibody-drug conjugate (ADC) specifically indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
How to Purchase Inotuzumab ozogamicin (Besponsa)?
Overseas Procurement
Patients may consult and purchase inotuzumab ozogamicin at hospital pharmacies or licensed drugstores in countries/regions where the medication is approved for marketing.
Due to potential price variations influenced by regional differences, exchange rate fluctuations, and other factors, patients should conduct budget planning prior to purchase.
Procurement through Medical Service Institutions
Patients may consult domestic overseas medical service institutions collaborating with international pharmacies or pharmaceutical companies.
These institutions typically provide legal import channels and offer professional consultation and guidance.
Precautions for the Use of Inotuzumab ozogamicin (Besponsa)
Monitoring for Hepatotoxicity Risk
Inotuzumab ozogamicin may cause severe hepatic injury, particularly sinusoidal obstruction syndrome (SOS, formerly known as veno-occlusive disease [VOD]).
During treatment, patients should undergo regular monitoring of liver function indicators (ALT/AST, bilirubin, etc.). Immediately discontinue the drug and seek medical attention if symptoms such as jaundice, ascites, or right upper abdominal pain occur.
Myelosuppression and Infection Prevention
The drug may cause neutropenia and thrombocytopenia. Complete blood count (CBC) monitoring should be performed weekly, and prophylactic anti-infective measures should be implemented if necessary.
Immediate medical intervention is required if febrile neutropenia develops.
Management of Infusion Reactions
Premedication with corticosteroids, antipyretic analgesics, and antihistamines is required before the first dose.
Closely monitor blood pressure and body temperature during infusion, and ensure emergency equipment is available to manage potential reactions such as chills and dyspnea.
Methods to Verify the Authenticity of Inotuzumab ozogamicin (Besponsa)
Verification of Packaging Labels
Clear display of the generic name (inotuzumab ozogamicin) and trade name (Besponsa).
Batch number, expiration date, and drug traceability code.
Verification of Drug Characteristics and Reconstitution
According to the package insert, authentic products are white to off-white lyophilized powder. After reconstitution, the solution should be clear or opalescent with no visible particles.
Immediately discontinue use if caking of the powder, turbidity of the solution, or abnormal discoloration is observed.
